Logo image of AKAN

AKANDA CORP (AKAN) Stock Fundamental Analysis

NASDAQ:AKAN - Nasdaq - CA00971M4039 - Common Stock - Currency: USD

1.57  -0.05 (-3.09%)

After market: 1.55 -0.02 (-1.27%)

Fundamental Rating

1

AKAN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. AKAN may be in some trouble as it scores bad on both profitability and health. AKAN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AKAN had negative earnings in the past year.
AKAN had a negative operating cash flow in the past year.
AKAN Yearly Net Income VS EBIT VS OCF VS FCFAKAN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -323.87%, AKAN is not doing good in the industry: 94.09% of the companies in the same industry are doing better.
The Return On Equity of AKAN (-706.22%) is worse than 82.26% of its industry peers.
Industry RankSector Rank
ROA -323.87%
ROE -706.22%
ROIC N/A
ROA(3y)-165.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKAN Yearly ROA, ROE, ROICAKAN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -5K -10K -15K -20K

1.3 Margins

AKAN has a Gross Margin (11.64%) which is in line with its industry peers.
AKAN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 11.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKAN Yearly Profit, Operating, Gross MarginsAKAN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

2

2. Health

2.1 Basic Checks

AKAN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AKAN has been increased compared to 1 year ago.
AKAN has a worse debt/assets ratio than last year.
AKAN Yearly Shares OutstandingAKAN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 50K 100K
AKAN Yearly Total Debt VS Total AssetsAKAN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 10M 20M 30M

2.2 Solvency

AKAN has an Altman-Z score of -10.47. This is a bad value and indicates that AKAN is not financially healthy and even has some risk of bankruptcy.
AKAN's Altman-Z score of -10.47 is on the low side compared to the rest of the industry. AKAN is outperformed by 77.96% of its industry peers.
AKAN has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.08, AKAN perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -10.47
ROIC/WACCN/A
WACC6.64%
AKAN Yearly LT Debt VS Equity VS FCFAKAN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 1.41 indicates that AKAN should not have too much problems paying its short term obligations.
The Current ratio of AKAN (1.41) is worse than 75.81% of its industry peers.
AKAN has a Quick Ratio of 1.41. This is a normal value and indicates that AKAN is financially healthy and should not expect problems in meeting its short term obligations.
AKAN's Quick ratio of 1.41 is on the low side compared to the rest of the industry. AKAN is outperformed by 67.74% of its industry peers.
Industry RankSector Rank
Current Ratio 1.41
Quick Ratio 1.41
AKAN Yearly Current Assets VS Current LiabilitesAKAN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

AKAN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -83.91%.
AKAN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -17.54%.
EPS 1Y (TTM)-83.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.13%
Revenue 1Y (TTM)-17.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%270.52%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AKAN Yearly Revenue VS EstimatesAKAN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
AKAN Yearly EPS VS EstimatesAKAN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AKAN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKAN Price Earnings VS Forward Price EarningsAKAN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKAN Per share dataAKAN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150 -200 -250

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

AKAN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKANDA CORP

NASDAQ:AKAN (1/30/2025, 8:03:46 PM)

After market: 1.55 -0.02 (-1.27%)

1.57

-0.05 (-3.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-01 2022-11-01/bmo
Earnings (Next)12-13 2022-12-13/bmo
Inst Owners0.49%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.74M
AnalystsN/A
Price TargetN/A
Short Float %1.05%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.81
P/FCF N/A
P/OCF N/A
P/B 0.38
P/tB 0.38
EV/EBITDA N/A
EPS(TTM)-286.63
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.08
FCFYN/A
OCF(TTM)-2.87
OCFYN/A
SpS1.95
BVpS4.12
TBVpS4.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -323.87%
ROE -706.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 11.64%
FCFM N/A
ROA(3y)-165.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 53.76%
Cap/Sales 62.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.41
Quick Ratio 1.41
Altman-Z -10.47
F-Score4
WACC6.64%
ROIC/WACCN/A
Cap/Depr(3y)72.05%
Cap/Depr(5y)N/A
Cap/Sales(3y)478.34%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-83.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.13%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-17.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%270.52%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y53.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y88.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.92%
OCF growth 3YN/A
OCF growth 5YN/A